WAKAMOTO PHARMACEUTICAL CO., LTD. started as a pioneering company for self-medication with the launch of a nutrient-rich, gastrointestinal remedy, “WAKAMOTO” medicine in 1929. We are holding contributions to everyone’s health as our societal mission in business.
In recent years, the environment surrounding the pharmaceutical industry has been undergoing major changes. In particular, the baby boomer generation will reach age 75 or over and enter the senior citizen demographic in 2025, and Japan will face increasingly lower birth rates and a more aged society. Meanwhile, sustained systemic reform efforts are advancing for the National Health Insurance system, while fundamental reform of the drug pricing system progresses in order to reduce the medical expense burden on the nation. These shifts are occurring with unprecedented speed.
Using our experience obtained from long history, we will engage in development of OTC pharmaceuticals to suit market needs, in conjunction with the government policy of “self-medication promotion” in the healthcare sector. In pharmaceutical business terms, we will also engage in research and development of the medications an ultra-aged society needs, in the form of specialty pharma specialized in the ophthalmic field. Toward that end, we have three goals.
1. To embody a challenger’s spirit, and build up the company to have pride and dreams.
2. To strengthen all departments with free innovation and proposals, and to build up the company in a profit-driven format while also increasing sales.
3. To always respect our corporate governance and maintain compliance, and ensure ethics and transparency societally.
Going forward, we will continue to proactively develop and launch diverse products tailored to public health needs, from clinical through OTC pharmaceuticals, and other health products.
All of us will come together as one and give our all to fulfill our corporate responsibilities to society, and to earn love and trust from everyone.
Thank you all for your continued understanding and support for WAKAMOTO PHARMACEUTICAL CO., LTD.
|Trade name||WAKAMOTO PHARMACEUTICAL CO., LTD.|
|Capital||3.395 billion yen|
|Business||Manufacture and sale of ethical drugs and non-prescription drugs|
|Number of Employees 315 （ as of the end of March, 2020 ）|
|Main Places of Business||Head Office||Tokyo|
|Branch Offices||Sapporo, Sendai, Kanto, Tokyo,
Nagoya, Hiroshima, and Fukuoka
|Head Office||2-2-2, Nihonbashi Honcho, Chuo-ku, Tokyo, 103-8330, Japan|
|April||1929||Incorporated a limited partnership company, "SOCIETY FOR NUTRITION AND PARENTING" in Shiba-koen Daimon, Tokyo, and launched "Wakamoto."|
|January||1933||Incorporated "SOCIETY FOR NUTRITION AND PARENTING CO., LTD." in Shiba-koen, Shiba-ku, Tokyo, and started manufacturing and selling a digestive, regulating, and nutritional agent, "Wakamoto."|
|December||1935||Changed the trade name to "WAKAMOTO HONPO SOCIETY FOR NUTRITION AND PARENTING CO., LTD."|
|July||1943||Changed the trade name to current "WAKAMOTO PHARMACEUTICAL CO., LTD."|
|May||1949||Listed on Tokyo Stock Exchange.|
|January||1962||Launched "Strong Wakamoto" with enrichment and enhancement of digestive enzymes, active lactobacillus, vitamin B1, vitamin B2, and nicotinic acid amide.|
|June||1968||Newly established Sagami Ohi Plant and a research laboratory in Oi-machi, Kanagawa.|
|August||1983||Launched a medicated toothpaste, "Coral." (currently "Coral ε")|
|September||1983||Listed on the first section of Tokyo Stock Exchange.|
|January||1989||Issued the 1st convertible corporate bond by secured collateral of the issue par value total amount of 4 billion yen.|
|May||1989||Launched a water soluble nonsteroidal anti-inflammatory ophthalmic solution, "Diclod Ophthalmic Solution 0.1%."|
|December||1994||Launched a lactobacillus preparation, "Wakamoto Intestinal Remedy."|
|November||1999||Launched the world's first thermal response gel technology applied ophthalmic solution, a therapeutic agent for glaucoma and ocular hypertension, "Rysmon TG Ophthalmic Solution."|
|November||2000||Launched a therapeutic agent for allergic conjunctivitis, "Zepelin Ophthalmic Solution 0.1%."|
|August||2002||Sagami Ohi Plant acquired environmental management systems ISO14001 certification.|
|November||2005||Launched a medicated toothpaste containing lactobacilli, "Avantbise."|
|July||2007||Launched a therapeutic agent for glaucoma and ocular hypertension, "Nipradilol Ophthalmic Solution 0.25%." (the product which first adopted an antiseptic free NP container)|
|December||2010||Launched an ophthalmic surgery adjuvant, "MaQaid Intravitreous Injection 40mg." (currently an ophthalmic surgery adjuvant/an ophthalmic adrenocortical hormone agent, "MaQaid Ophthalmic Injection 40mg")|
|April||2014||Relocated the head office to 2-2-2, Nihonbashi Honcho, Chuo-ku, Tokyo.|
|October||2015||Launched a supplement, "Optiaid DE."|
|April||2017||Launched a processed food containing lactobacilli, "Avantbise Oral Tablet."|
|October||2018||Launched an allegy-specific ophthalmic drug, "アレジフェンス（OTC product of ACITAZANOLAST HYDRATE OPHTHALMIC SOLUTION 0.1%）"|
|August||2019||Launched a food with functional claims, "Optiaid ML MACULAR."|